{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000004","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.442041+00:00","generated_at":"2026-05-28T06:24:37.278714+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Emergent receives $50M BARDA CYFENDUS option and $20M DoD BioThrax option","bullets":["BARDA awarded $50M option for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted); deliveries through April 2025.","DoD exercised $20M option for BioThrax (Anthrax Vaccine Adsorbed); $7M delivered Dec 2024, balance in 2025.","Both modifications supplement existing IDIQ contracts with BARDA (HHSO100201600030C) and DoD (W911SR24D0001)."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000004","json":"https://secwatch.observer/filing/0001367644-25-000004.json","markdown":"https://secwatch.observer/filing/0001367644-25-000004.md","text":"https://secwatch.observer/filing/0001367644-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/0001367644-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000004/ebs-20241212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:24:37.278714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}